Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques

Aisha A. AlJanahi,Cicera R. Lazzarotto,Shirley Chen,Tae-Hoon Shin,Stefan Cordes,Xing Fan,Isabel Jabara,Yifan Zhou,David J. Young,Byung-Chul Lee,Kyung-Rok Yu,Yuesheng Li,Bradley Toms,Ilker Tunc,So Gun Hong,Lauren L. Truitt,Julia Klermund,Geoffroy Andrieux,Miriam Y. Kim,Toni Cathomen,Saar Gill,Shengdar Q. Tsai,Cynthia E. Dunbar
DOI: https://doi.org/10.1016/j.ymthe.2021.06.016
IF: 12.91
2022-01-01
Molecular Therapy
Abstract:<p>The programmable nuclease technology CRISPR/Cas9 has revolutionized gene editing in the last decade. Due to the risk of off-target editing, accurate and sensitive methods for off-target characterization are crucial prior to applying CRISPR/Cas9 therapeutically. Here, we utilized a rhesus macaque model to compare the predictive values of CIRCLE-seq, an <em>in vitro</em> off-target prediction method, with <em>in silico</em> prediction (ISP) based solely on genomic sequence comparisons. We use AmpliSeq HD error-corrected sequencing to validate off-target sites predicted by CIRCLE-seq and ISP for a <em>CD33</em> gRNA with thousands of off-target sites predicted by ISP and CIRCLE-seq. We found poor correlation between the sites predicted by the two methods. When almost 500 sites predicted by each method were analyzed by error-corrected sequencing of hematopoietic cells following transplantation, 19 off-target sites revealed insertion/deletion mutations. Of these sites, 8 were predicted by both methods, 8 by CIRCLE-seq only, and 3 by ISP only. The levels of cells with these off-target edits exhibited no expansion or abnormal behavior <em>in vivo</em> in animals followed for up to 2 years. In addition, we utilized an unbiased method termed CAST-Seq to search for translocations between the on-target site and off-target sites present in animals following transplantation, detecting one specific translocation that persisted in blood cells for at least one year following transplantation. In conclusion, neither CIRCLE-seq or ISP predicted all sites, and a combination of careful gRNA design, followed by screening for predicted off-target sites in target cells by multiple methods may be required for optimizing safety of clinical development.</p>
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?